Brian Taylor Slingsby

Brian Taylor Slingsby discloses dealings in Mineralys Therapeutics, Inc. to SEC (Form 4). We count 9 filings; the first trade dates from 14 February 2023 and the latest from 22 September 2026.

On the open market, the record shows 2 purchases worth €6.9M and 3 sales worth €46.8M. The net balance comes to €39.9M on the selling side. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 1 share grant. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 24 September 2026, the filings show an open-market sale worth €2.6M in Mineralys Therapeutics, Inc. The clock since the last published purchase (25 April 2025) now reads 563 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.